Antibody engineering: facing new challenges in cancer therapy

被引：45

作者：

Sanz, L ^{[1
]}

Cuesta, AM ^{[1
]}

Compte, M ^{[1
]}

Alvarez-Vallina, L ^{[1
]}

机构：

[1] Hosp Univ Puerta Hierro, Serv Inmunol, Madrid, Spain

来源：

ACTA PHARMACOLOGICA SINICA | 2005年 / 26卷 / 06期

关键词：

immunoglobulin fragments; monoclonal antibodies; antibody formation; gene therapy; recombinant proteins; biomedical engineering;

D O I：

10.1111/j.1745-7254.2005.00135.x

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Antibody-based therapeutics are beginning to realize the promise enclosed in their early denomination as "magic bullets". Initial disappointment has turned into clinical and commercial success, and engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials. Recent structural and functional data have allowed the design of a new generation of therapeutic antibodies, with strategies ranging from complement-mediated and antibody-dependant cellular cytotoxicity enhancement to improved cytotoxic payloads using toxins, drugs, radionucleids and viral delivery. This review considers the structure of different types of recombinant antibodies, their mechanism of action and how their efficacy has been increased using a broad array of approaches. We will also focus on the additional benefits offered by the use of gene therapy methods for the in vivo production of therapeutic antibodies.

引用

页码：641 / 648

页数：8

共 50 条

[1] Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors [J].